- Home
- NPCE
NPCE
Neuropace Inc.
as 01-17-2025 4:00pm EST
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 355.5M | IPO Year: | 2021 |
| Target Price: | $15.83 | AVG Volume (30 days): | 86.9K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.45 - $18.15 | Next Earning Date: | 03-04-2025 |
| Revenue: | $76,452,000 | Revenue Growth: | 27.00% |
| Revenue Growth (this year): | 23.46% | Revenue Growth (next year): | 14.64% |
Stock Insider Trading Activity of Neuropace Inc. (NPCE)
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
NeuroPace Preliminary Q4 Revenue Increases; Shares Rise After Hours
GlobeNewswire
10 days ago
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates
Zacks
25 days ago
NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock?
GlobeNewswire
a month ago
NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
a month ago
NeuroPace to Host Investor Day on January 28th in New York City
Zacks
a month ago
Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet
GlobeNewswire
a month ago
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
GlobeNewswire
2 months ago
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
Compare NPCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NPCE Neuropace Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.